351 results on '"Dahan L"'
Search Results
2. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study
3. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
4. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
5. Risk factors of exocrine and endocrine pancreatic insufficiency after pancreatic resection: A multi-center prospective study
6. Facteurs de risques d’insuffisance pancréatique exocrine et endocrine après exérèse pancréatique : étude prospective multicentrique
7. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
8. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
9. Biostability Assessment of Flexible Parylene C-based Implantable Sensor in Wireless Chronic Neural Recording
10. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
11. LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)
12. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
13. Cancers du pancréas : articulation entre la recherche fondamentale et la recherche clinique
14. Quel traitement adjuvant de l’adénocarcinome du pancréas aujourd’hui : quelles perspectives ?
15. Traitement adjuvant du cancer colorectal : l’aspirine, une biothérapie ciblée ?
16. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer
17. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone
18. LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
19. 1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
20. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
21. Supplement to: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
22. Comment surveiller les patients opérés à visée curative d’un cancer colorectal ?
23. Nanotailoring of Nanocomposite Hydrogels Containing POSS
24. POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy
25. Gemcitabine : CDA, hENT1 et dCK
26. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer
27. OC-086 Surgery alone vs chemoradiotherapy followed by surgery for stage I and II oesophageal cancer: final analysis of a randomised controlled phase III trial—FFCD 9901
28. 1566TiP PRODIGE 65 - UCGI 36 - GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma
29. LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy
30. 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial
31. 1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial
32. Le cancer du pancréas : un challenge en oncologie digestive
33. Actualité de l’ASCO 2004 par localisations: Cancer du côlon
34. LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
35. 1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
36. Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
37. Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI)
38. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
39. Adénocarcinomes du bas œsophage et du cardia: quelle chimiothérapie ou chimioradiothérapie dans le traitement des récidives et des métastases?
40. 609TiPPRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation
41. FFCD Prodige 31 Reminnet: a european, multicentre, phase II/III randomized double-blind, placebo-controlled study evaluating
42. REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
43. On the Performance of Tree-Based Antennas for SLF-VLF Signal Reception
44. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial
45. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
46. Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial)
47. Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer
48. Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
49. Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations
50. PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.